Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer

Lung Cancer

Volumn 35, Issue 2, 2002, Pages 209-214

  Niho, Seiji ^a   Ohe, Yuichiro ^a,b   Kakinuma, Ryutaro ^a   Kubota, Kaoru ^a   Matsumoto, Taketoshi ^a   Ohmatsu, Hironobu ^a   Goto, Koichi ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Non small cell lung cancer; Phase II study; Weekly

Indexed keywords

CISPLATIN; DOCETAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0036163117     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00328-2     Document Type: Article

References (35)

1. Docetaxel (taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG)
2. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
3. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
4. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
5. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
6. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
7. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
8. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
9. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
10. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study
11. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
12. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
13. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
14. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis
15. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
16. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
17. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer
18. Phase I studies of cisplatin and docetaxel administered by 3 consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients
19. Reporting results of cancer treatment
20. Toxicity grading criteria of the Japan clinical oncology group
21. Optimal two-stage designs for phase II clinical trials
22. Nonparametric estimation from incomplete observations
23. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
24. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
25. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
26. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
27. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian lung cancer project
28. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
29. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
30. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
31. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer
32. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma
33. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
34. Coping with toxicities of docetaxel (taxotere)
35. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer